FindTrial
Sign In

To know the outcome of specially prepared blood derivative on treatment of decay of bone due to certain cancer medicines commonly termed as MRONJ (Medicine related osteonecrosis of jaw)

Analysis of risk factors and treatment outcomes of osteonecrosis of the jaw in cancer patients receiving anti-resorptives: Audit of cases seen in dental services -TMH

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/09/009615
Enrollment
300
Registered
2017-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- malignant disease and bony metastases receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and Denosumab

Interventions

None listed

Sponsors

no
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients referred to the dental services of TMH, receiving/ prior to receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and Denosumab

Exclusion criteria

Exclusion criteria: 1.Patients who are referred to dental department but not receiving antiresorptive drugs. 2.Patients unwilling to give consent

Design outcomes

Primary

MeasureTime frame
1. Osteonecrosis of Jaw 2. Local and systemic factors predisposing osteonecrosis of jaw.Timepoint: Each three months upto 2 years from the date of enrollment.—

Secondary

MeasureTime frame
Pain, Infection, Pus discharge from jaw bones progressing to osteonecrosis of jawTimepoint: Each three months up to 2 years—

Countries

India

Contacts

Public ContactDr Sandeep Gurav

Tata Memorial Hospital

drsandeepgurav@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026